FDA Classifies Endoscopic Traction Device as Moderate Risk
Published Date: 6/22/2026
Rule
Summary
The FDA is officially putting the endoscopic traction device into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while making it easier for patients to get access to this cool medical tool. The new rules took effect on June 22, 2026, and could speed up innovation without extra costs for makers.
Analyzed Economic Effects
6 provisions identified: 3 benefits, 3 costs, 0 mixed.
Device Classified into Class II
The FDA officially classified the endoscopic traction device as Class II (special controls), effective June 22, 2026 (classification applicable June 13, 2022). FDA says this classification provides reasonable assurance of safety and effectiveness and will enhance patients' access by reducing regulatory burdens.
Device Subject to 510(k) Premarket Notices
FDA states that endoscopic traction devices are subject to premarket notification requirements under section 510(k) of the FD&C Act (i.e., a 510(k) submission is required) at this time.
Special Controls Require Safety Testing
The final order codifies special controls that require in vivo performance testing, non-clinical performance testing, usability assessment, sterility and biocompatibility data, shelf-life demonstration, and specific labeling (including recommended training and safe anatomical locations).
Manufacturers Must Meet Detailed Controls
Manufacturers must meet the codified special controls (testing for perforation, bleeding, device deployment, tensile strength, magnet strength if applicable, sterility, biocompatibility, shelf life, and labeling including recommended training and lesion size guidance) to fall within Class II and avoid automatic Class III assignment.
De Novo Enables Predicate Use for Future Devices
FDA states that because this device was classified via the De Novo process, the endoscopic traction device can serve as a predicate for future devices of that type, allowing other sponsors to use the less burdensome 510(k) process rather than a De Novo or premarket approval.
Device Is Prescription-Only
The final order identifies the endoscopic traction device as a prescription device (prescription use only) and notes prescription devices are exempt from the requirement for adequate directions for layperson use under section 502(f)(1) of the FD&C Act, provided conditions of 21 CFR 801.109 are met.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19350, Nonclinical Testing Terminology
The FDA is updating its rules to replace the words “animal” tests with “nonclinical” tests, making room for new, smarter ways to check drug safety without relying only on animal testing. This change affects drug makers and researchers but won’t add new costs or requirements. The rule kicks in on February 4, 2027, and comments are open until December 7, 2026.
2026-19349, Nonclinical Testing Terminology
The FDA wants to update its rules by swapping out the word “animal” tests for “nonclinical” tests to better reflect modern science. This change affects drug safety testing rules, encourages new testing methods that might use fewer animals, and doesn’t add any new costs or requirements. Anyone interested can comment on these changes until December 7, 2026.
Previous / Next Documents
Previous: 2026-12444, Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Light-Projecting Measuring Device
The FDA is officially putting the endoscopic light-projecting measuring device into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while speeding up patient access to cool new tech. The new rules took effect June 22, 2026, and could save time and money for makers and users alike.
Next: 2026-12448, Rescinding the Requirement for Electronic Logging Device Operator's Manual Located in Commercial Motor Vehicles
Starting July 22, 2026, commercial truck drivers no longer have to keep a paper copy of their electronic logging device (ELD) manual in their vehicles. Drivers still need to know how to use their ELDs to keep accurate records and show them during inspections. This change cuts down on paperwork without hurting safety or costing extra money.